Cited by 1,180Inflammatory Bowel DiseaseOcular Diseases and Behçet’s SyndromeMicroscopic Colitis

The DOI matches its Crossref record; 309 of the 309 references it cites were found in a registry or an index.

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Open access

Harbord, Marcus, Eliakim, Rami, Bettenworth, Dominik, Karmiris, Konstantinos, Katsanos, Konstantinos, Kopylov, Uri, Kucharzik, Torsten, Molnár, Tamás, Raine, Tim, Sebastian, Shaji, de Sousa, Helena Tavares, Dignass, Axel, Carbonnel, Franck, for the European Crohn’s and Colitis Organisation [ECCO·2017·Journal of Crohn's and Colitis

DOI 10.1093/ecco-jcc/jjx009

Open this paper in CoChat — free account Open PDF

Abstract

The treatment strategy for ulcerative colitis [UC] is mainly based on the severity, distribution [proctitis, left-sided, extensive]1 and pattern of disease. The latter includes relapse frequency, disease course, response to previous medications, side effects of medication, and extra-intestinal manifestations. Age at onset, and disease duration are also important factors. It is important to distinguish patients with severe UC necessitating hospital admission from those with mild or moderately active disease who can be managed as outpatients. The best validated and most widely used index for identifying severe UC remains that of Truelove and Witts.2 Patients with bloody stool frequency ≥ 6/day and a tachycardia [> 90 min−1], or temperature > 37.8°C, or anaemia [haemoglobin < 10.5 g/dl], or an elevated erythrocyte sedimentation rate [ESR] [> 30 mm/h] have severe UC. Only one additional criterion in addition to the bloody stool frequency ≥ 6/day is needed to define a severe attack.3,4 In practice, a C-reactive protein [CRP] of 30 mg/l can be substituted for the ESR. A mesalamine 1-g suppository once daily is the preferred initial treatment for mild or moderately active proctitis [EL1]. Mesalamine foam or enemas are an alternative [EL1], but suppositories deliver the drug more effectively to the rectum and are better tolerated [EL3]. Topical mesalamine is more effective than topical steroids [EL1]. Combining topical mesalamine with oral mesalamine or topical steroids is more effective [EL2] Refractory proctitis may require treatment with systemic steroids, immunosuppressants, and/or biologics [EL4] Topical mesalamine [5-aminosalicylic acid or 5-ASA] is the first-line therapy for proctitis. A Cochrane systematic review of 38 clinical trials of treatment of proctitis and left-sided colitis confirmed its superiority over placebo for inducing symptomatic, endoscopic, histological response and remission.5 The pooled odds ratio [OR] was: 8.3 for symptomatic remission (8 trials, 95% confidence interval [CI] 4.28–16.12; p < 0.00001); 5.3 for endoscopic remission [7 trials, 95% CI 3.15–8.92; p < 0.00001]; and 6.3 for histological remission [5 trials, 95% CI 2.74–14.40; p < 0.0001]. Suppositories are more appropriate than enemas in proctitis as they better target the site of inflammation and are more acceptable for patients.6 There is no dose response for topical therapy above a dose of 1 g 5-ASA daily.5,7 Once-daily topical therapy is as effective as divided doses.8,9 A meta-analysis found no difference between oral and topical 5-ASA for induction of remission (risk ratio [RR] for no remission with topical 5-ASA: 0.82, 95% CI 0.52–1.28) or time to remission [24.8 vs 25.5 days, respectively], but the trials included in this meta-analysis enrolled patients with UC of any extent, not specifically proctitis.10 In the single trial that included only patients with proctitis, rectal 5-ASA was more effective than oral 5-ASA alone.11 However, if oral 5-ASA is used alone, 3.6 g of a pH-dependent release preparation appears to be more effective than lower doses or placebo.12 Moreover in patients with proctosigmoiditis, 5-ASA granules rather than tablets are more likely to obtain clinical [78% vs 55%, p < 0.001] and endoscopic [67% vs 43%, p < 0.001] remission.13 The combination of oral and topical 5-ASA is more effective than either alone in patients with disease extending < 50 cm from the anal verge,14 although there is no trial of combination therapy for proctitis alone. Combining topical 5-ASA and topical steroids also helps: beclomethasone dipropionate [3 mg] and 5-ASA [2 g] enemas produced significantly better clinical, endoscopic, and histological improvement than either agent alone.15 Two meta-analyses have shown that topical 5-ASA is more effective than topical steroids, whether assessing symptomatic, endoscopic, or histological remission.16 Consequently topical steroids be to patients who have an or who are to topical A trial shown that g rectal foam alone is more than placebo in inducing remission at in patients with mild to vs p < drug not with topical and endoscopic be confirmed in those with to with oral topical 5-ASA and/or topical Refractory proctitis may require treatment with systemic steroids, or The of proctitis is in to moderately active left-sided ulcerative colitis be with an ≥ 1 with oral mesalamine ≥ [EL1], is more effective than oral or topical or topical steroids alone [EL1]. Topical mesalamine is more effective than topical steroids [EL1]. Once-daily with mesalamine is as effective as divided doses are appropriate in patients with to severe and in those with mild who not to mesalamine [EL1]. beclomethasone dipropionate and as oral in patients with mild to moderately active ulcerative colitis can be in patients with mild to disease who are or to left-sided colitis is an for hospital admission oral and topical 5-ASA is the first-line therapy for mild to moderately active left-sided with an of to remission o

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/ecco-jcc/jjx009

Cites

309 of 309 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P. J., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A. D., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,910
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., Caprilli, R., Colombel, J., Gasché, C., Geboes, K., et al. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/269076 · Cited by 3,410
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A. A., Rachmilewitz, D., Lichtiger, S., D’Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,184
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P. J., Sands, B. E., Hanauer, S. B., Colombel, J., Sandborn, W. J., Assche, G. V., Axler, J. L., Kim, H. J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,892
Cortisone in Ulcerative Colitis
Truelove, S. C., & Witts, L. J. (1955) · BMJ · doi:10.1136/bmj.2.4947.1041 · Cited by 2,793
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Assche, G. V., Haens, G. D., Carbonez, A., & Rutgeerts, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,012
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Lichtiger, S., Present, D. H., Kornbluth, A. A., Gelernt, I. M., Bauer, J. J., Galler, G. W., Michelassi, F., & Hanauer, S. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302601 · Cited by 1,715
Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
Sandborn, W. J., Assche, G. V., Reinisch, W., Colombel, J., D’Haens, G., Wolf, D. C., Kron, M., Tighe, M. B., Lazar, A., & Thakkar, R. B. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.10.032 · Cited by 1,268
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
Rahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., Munter, P. D., D’Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 1,247
Self-citation
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
Faubion, W. A., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26279 · Cited by 1,144
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial
Rembacken, B., Snelling, A. M., Hawkey, P. M., Chalmers, D. M., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,100
Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study
Järnerot, G., Hertervig, E., Friis–Liby, I., Blomquist, L., Karlén, P., Grännö, C., VILIEN, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,092
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Panaccione, R., Ghosh, S. K., Middleton, S. J., Márquez, J. R., Scott, B. B., Flint, L., van Hoogstraten, H. J. F., Chen, A. C., Zheng, H., Danese, S., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.052 · Cited by 983
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
Sandborn, W. J., Feagan, B. G., Marano, C. W., Zhang, H., Strauss, R. S., Johanns, J., Adedokun, O. J., Guzzo, C. A., Colombel, J., Reinisch, W., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.048 · Cited by 944
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
Rahier, J., Magro, F., Abreu, C., Armuzzi, A., Ben‐Horin, S., Chowers, Y., Cottone, M., de Ridder, L., Doherty, G. A., Ehehalt, R., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.12.013 · Cited by 925
Self-citation
Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis
Rossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
Colombel, J., Rutgeerts, P. J., Reinisch, W., Esser, D., Wang, Y., Lang, Y., Marano, C. W., Strauss, R. S., Oddens, B. J., Feagan, B. G., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.054 · Cited by 918
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Reinisch, W., Sandborn, W. J., Hommes, D. W., D’Haens, G., Hanauer, S. B., Schreiber, S., Panaccione, R., Fedorak, R. N., Tighe, M. B., Huang, B., et al. (2011) · Gut · doi:10.1136/gut.2010.221127 · Cited by 891
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Casteele, N. V., Ferrante, M., Assche, G. V., Ballet, V., Compernolle, G., Steen, K. V., Simoens, S., Rutgeerts, P. J., Gils, A., & Vermeire, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.031 · Cited by 889
The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease
Harbord, M., Annese, V., Vavricka, S. R., Allez, M., Acosta, M. B., Boberg, K. M., Burisch, J. M., Vos, M. D., de Vries, A., Dick, A. D., et al. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv213 · Cited by 827
Self-citation
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S. K., Panés, J., Vranic, I. I., Su, C. G., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
Predicting outcome in severe ulcerative colitis.
Travis, S. P. L., Farrant, J. M., Ricketts, C., Nolan, D. J., Mortensen, N. M., Kettlewell, M. G. W., & Jewell, D. P. (1996) · Gut · doi:10.1136/gut.38.6.905 · Cited by 787
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
Cleynen, I., Boucher, G., Jostins, L., Schumm, L. P., Zeißig, S., Ahmad, T., Andersen, V. C., Andrews, J. M., Annese, V., Brand, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00465-1 · Cited by 784
Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
Kruis, W., SCHÜTZ, E., Fric, P., Fixa, B., Judmaier, G., & Stolte, M. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00225.x · Cited by 774
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
Sandborn, W. J., Feagan, B. G., Marano, C. W., Zhang, H., Strauss, R. S., Johanns, J., Adedokun, O. J., Guzzo, C. A., Colombel, J., Reinisch, W., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.010 · Cited by 730
Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
Solberg, I. C., Lygren, I., Jahnsen, J., Aadland, E., Høie, O., Cvancarova, M., Bernklev, T., Henriksen, M., Sauar, J., Vatn, M. H., et al. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520802600961 · Cited by 729
Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study
Grainge, M. J., West, J., & Card, T. R. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61963-2 · Cited by 729
Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression
Turner, D., Walsh, C. M., Steinhart, A. H., & Griffiths, A. M. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.09.033 · Cited by 659
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Yoo, D., Hrycaj, P., Miranda, P., Ramiterre, E., Piotrowski, M., Shevchuk, S. V., Kovalenko, V., Prodanović, N., Abello-Banfi, M., Gutiérrez-Ureña, S. R., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203090 · Cited by 654
European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases
Dignass, A. U., Gasché, C., Bettenworth, D., Birgegård, G., Danese, S., Gisbert, J. P., Gomollón, F., Iqbal, T. H., Katsanos, K. H., Κoutroubakis, I. E., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jju009 · Cited by 649
Self-citation
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
Laharie, D., Bourreille, A., Branche, J., Allez, M., Bouhnik, Y., Filippi, J., Zerbib, F., Savoye, G., Nachury, M., Moreau, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61084-8 · Cited by 644
Self-citation
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review
Fraser, A. G. (2002) · Gut · doi:10.1136/gut.50.4.485 · Cited by 631
Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease
Maser, E. A., Villela, R., Silverberg, M. S., & Greenberg, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.025 · Cited by 613
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Park, W., Hrycaj, P., Jeka, S., Kovalenko, V., Lysenko, G., Miranda, P., Mikažāne, H., Gutiérrez-Ureña, S. R., Lim, M. J., Lee, Y.-A., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203091 · Cited by 607
Impact of Clostridium difficile on Inflammatory Bowel Disease
Issa, M., Vijayapal, A., Graham, M. B., Beaulieu, D. B., Otterson, M. F., Lundeen, S. J., Skaros, S., Weber, L. R., KOMOROWSKI, R. A., Knox, J. F., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.12.028 · Cited by 570
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis
Kane, S. V., Huo, D., Aikens, J. E., & Hanauer, S. B. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01383-9 · Cited by 568
Microscopic activity in ulcerative colitis: what does it mean?
Riley, S. A., Mani, V., Goodman, M. J., Dutt, S., & Herd, M. E. (1991) · Gut · doi:10.1136/gut.32.2.174 · Cited by 562
INTENSIVE INTRAVENOUS REGIMEN FOR SEVERE ATTACKS OF ULCERATIVE COLITIS
Truelove, S. C., & Jewell, D. P. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90552-2 · Cited by 549
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
Timmer, A., Patton, P. H., Chande, N., McDonald, J. W., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000478.pub4 · Cited by 529
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
Ardizzone, S., Maconi, G., Russo, A., Imbesi, V., Colombo, E., & Porro, G. B. (2005) · Gut · doi:10.1136/gut.2005.068809 · Cited by 503
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Wang, Y., Parker, C. E., Bhanji, T., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000543.pub4 · Cited by 500
Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
Assche, G. V., Magdelaine–Beuzelin, C., D’Haens, G., Baert, F., Noman, M., Vermeire, S., Ternant, D., Watier, H., Paintaud, G., & Rutgeerts, P. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.004 · Cited by 493
Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis
Bitton, A., Peppercorn, M. A., Antonioli, D. A., Niles, J. L., Shah, S. A., Bousvaros, A., Ransil, B. J., Wild, G., Cohen, A., Edwardes, M. D. D., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.20912 · Cited by 489
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Wang, Y., Parker, C. E., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000544.pub4 · Cited by 482
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis
Zocco, M. A., Verme, L. Z. D., Cremonini, F., Piscaglia, A. C., Nista, E. C., Candelli, M., Novi, M., Rigante, D., Cazzato, I. A., Ojetti, V., et al. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02927.x · Cited by 472
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y., & Hibi, T. (2006) · Gut · doi:10.1136/gut.2005.081794 · Cited by 462
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.
Hawthorne, A. B., Logan, R. F., Hawkey, C. J., Foster, P. N., Axon, A. T. R., Swarbrick, E. T., Scott, B. B., & Lennard‐Jones, J. E. (1992) · BMJ · doi:10.1136/bmj.305.6844.20 · Cited by 451
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
Sandborn, W. J., Feagan, B. G., Wolf, D. C., D’Haens, G., Vermeire, S., Hanauer, S. B., Ghosh, S. K., Smith, H., Cravets, M. W., Frohna, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513248 · Cited by 451
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Brandse, J. F., BRINK, G. R. V. D., Wildenberg, M. E., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.016 · Cited by 434
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
Kane, S. V., Cohen, R. D., Aikens, J. E., & Hanauer, S. B. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04683.x · Cited by 429
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study
Sands, B. E., Tremaine, W. J., Sandborn, W. J., Rutgeerts, P. J., Hanauer, S. B., Mayer, L., Targan, S. R., & Podolsky, D. K. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200105000-00001 · Cited by 420
Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
Bressler, B. L., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., Panaccione, R., Steinhart, A. H., Tse, F., Feagan, B. G., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.001 · Cited by 414
A National Survey of the Prevalence and Impact of Clostridium difficile Infection Among Hospitalized Inflammatory Bowel Disease Patients
Nguyen, G. C., Kaplan, G. G., Harris, M. L., & Brant, S. R. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01780.x · Cited by 400
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis
D’Haens, G., Lemmens, L., Nevens, F., Hiele, M. I., Rutgeerts, P. J., Vandeputte, L., Peeters, M., Vermeire, S., Geboes, K., Acker, F. V., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.23983 · Cited by 392
Early Postoperative Complications are not Increased in Patients with Crohn's Disease Treated Perioperatively with Infliximab or Immunosuppressive Therapy
Colombel, J., Loftus, E. V., Tremaine, W. J., Pembérton, J. H., Wolff, B. G., Young‐Fadok, T. M., Harmsen, W. S., Schleck, C. D., & Sandborn, W. J. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04148.x · Cited by 381
Randomized Controlled Trial of the Effect of Bifidobacteria-Fermented Milk on Ulcerative Colitis
Ishikawa, H., Akedo, I., Umesaki, Y., Tanaka, R., Imaoka, A., & Otani, T. (2003) · Journal of the American College of Nutrition · doi:10.1080/07315724.2003.10719276 · Cited by 369
Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohnʼs Disease, and Pouchitis: Meta-analysis of Randomized Controlled Trials
Shen, J., Zuo, Z.-X., & Mao, A.-P. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000437495.30052.be · Cited by 364
Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis
Shah, S. C., Colombel, J., Sands, B. E., & Narula, N. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.01.015 · Cited by 362
Intravenous Cyclosporin in Ulcerative Colitis: A Five-Year Experience
Cohen, R. D., Stein, R., & Hanauer, S. B. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01149.x · Cited by 361
CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS
Misiewicz, J. J., Lennard‐Jones, J. E., Connell, A. M., Baron, J. H., & Jones, F. A. (1965) · The Lancet · doi:10.1016/s0140-6736(65)90972-4 · Cited by 360
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
Marteau, P. R., Probert, C. S., Lindgren, S. C., Gassul, M., Tg, T., Dignass, A., Befrits, R., Midhagen, G., Rademaker, J., & FOLDAGER, M. (2005) · Gut · doi:10.1136/gut.2004.060103 · Cited by 360
Self-citation
Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology
Nguyen, G. C., Bernstein, C. N., Bitton, A., Chan, A. K. C., Griffiths, A. M., Leontiadis, G. I., Geerts, W. H., Bressler, B. L., Butzner, J. D., Carrier, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.042 · Cited by 354
Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
Kamm, M. A., Sandborn, W. J., Gassull, M. A., Schreiber, S., Jackowski, L., Butler, T., Lyne, A., Stephenson, D., Palmen, M. J. H. J., & Joseph, R. E. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.10.011 · Cited by 352
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Nanda, K. S., Cheifetz, A. S., & Moss, A. C. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.363 · Cited by 345
A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)
Dissanayake, A. S., & Truelove, S. C. (1973) · Gut · doi:10.1136/gut.14.12.923 · Cited by 342
Intensive intravenous treatment of ulcerative colitis
Järnerot, G., Rolny, P., & Sandberg–Gertzén, H. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90201-x · Cited by 337
Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic Trial
Jewell, D. P., & Truelove, S. C. (1974) · BMJ · doi:10.1136/bmj.4.5945.627 · Cited by 335
Systematic review with meta‐analysis: the efficacy of a second anti‐ TNF in patients with inflammatory bowel disease whose previous anti‐ TNF treatment has failed
Gisbert, J. P., Marín, A. C., McNicholl, A. G., & Chaparro, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13083 · Cited by 321
Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial
Hanauer, S. B., Sandborn, W. J., Kornbluth, A. A., Katz, S., Safdi, M. A., Woogen, S. D., Regalli, G., Yeh, C., Smith-Hall, N., & Ajayi, F. O. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00248.x · Cited by 320
Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
Yanai, H. A., Lichtenstein, L., Assa, A., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.029 · Cited by 316
Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.
Marshall, J. K., & Irvine, E. J. (1997) · Gut · doi:10.1136/gut.40.6.775 · Cited by 315
Epidermal Growth Factor Enemas with Oral Mesalamine for Mild-to-Moderate Left-Sided Ulcerative Colitis or Proctitis
Sinha, A., Nightingale, J. M. D., West, K. P., Berlanga-Acosta, J., & Playford, R. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013136 · Cited by 303
Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study
Kappelman, M. D., Horváth–Puhó, E., Sandler, R. S., Rubin, D. T., Ullman, T. A., Pedersen, L. H., Baron, J. A., & Sørensen, H. T. (2011) · Gut · doi:10.1136/gut.2010.228585 · Cited by 303
Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis
Moskovitz, D. N., Assche, G. V., Maenhout, B., Arts, J., Ferrante, M., Vermeire, S., & Rutgeerts, P. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.001 · Cited by 296
Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
Ford, A. C., Achkar, J., Khan, K. J., Kane, S. V., Talley, N. J., Marshall, J. K., & Moayyedi, P. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.67 · Cited by 295
Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial
Oren, R., Arber, N., Odes, S., Moshkowitz, M., Keter, D., Pomeranz, I. S., Ron, Y., Reisfeld, I., Broide, E., Lavy, A., et al. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613046 · Cited by 295
Self-citation
Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease.
Takeuchi, K., Smale, S., Premchand, P., Maiden, L., Sherwood, R., Thjódleifsson, B., Björnsson, E., & Bjarnason, I. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00980-8 · Cited by 293
Out-patient Treatment of Ulcerative Colitis
Baron, J. H., Connell, A. M., Kanaghinis, T., Lennard‐Jones, J. E., & Jones, F. A. (1962) · BMJ · doi:10.1136/bmj.2.5302.441 · Cited by 291
Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second‐line medical therapy or surgery
Ho, G., Mowat, C., Goddard, C., Fennell, J., Shah, N., Prescott, R. J., & Satsangi, J. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01945.x · Cited by 287
Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis.
Chapman, R. W., Selby, W. S., & Jewell, D. P. (1986) · Gut · doi:10.1136/gut.27.10.1210 · Cited by 285
Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial.
Breuer, R. I., Soergel, K. H., Lashner, B. A., Christ, M. L., Hanauer, S. B., Vanagunas, A., Harig, J. M., Keshavarzian, A., ROBINSON, M. G., Sellin, J. H., et al. (1997) · Gut · doi:10.1136/gut.40.4.485 · Cited by 282
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Roblin, X., Marotte, H., Rinaudo, M., Tedesco, É. D., Carla-Moreau, A., Phelip, J., Genin, C., Peyrin‐Biroulet, L., & Paul, S. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.010 · Cited by 277
Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis
Lindgren, S. C., Flood, L., Kilander, A. F., Löfberg, R., Persson, T., & Sjödahl, R. I. (1998) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199810000-00003 · Cited by 274
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial
Williams, J. G., Alam, M. F., Alrubaiy, L., Arnott, I. D., Clement, C., Cohen, D. R., Gordon, J. N., Hawthorne, A. B., Hilton, M., Hutchings, H. A., et al. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30003-6 · Cited by 271
Self-citation
Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis
Lichtenstein, G. R., Kamm, M. A., Boddu, P., Gubergrits, N. B., Lyne, A., Butler, T., Lees, K., Joseph, R. E., & Sandborn, W. J. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.10.025 · Cited by 268
An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
Gibson, D. J., Heetun, Z. S., Redmond, C. E., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.041 · Cited by 267
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
Travis, S. P. L., Danese, S., Kupčinskas, L., Alexeeva, O., D’Haens, G., Gibson, P. R., Moro, L., Jones, R., Ballard, E. D., Masure, J. A., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-304258 · Cited by 262
Controlled trial of bowel rest in the treatment of severe acute colitis.
McIntyre, P. B., Powell-Tuck, J., Wood, S., Lennard‐Jones, J. E., Lerebours, É., Hecketsweiler, P., Galmiche, J. P., & Colin, R. (1986) · Gut · doi:10.1136/gut.27.5.481 · Cited by 255
Clostridium difficile and inflammatory bowel disease
Issa, M., Ananthakrishnan, A. N., & Binion, D. G. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20500 · Cited by 253
Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications
Randall, J. K., Singh, B., Warren, B. F., Travis, S. P. L., Mortensen, N. J. M., & George, B. D. (2010) · British journal of surgery · doi:10.1002/bjs.6874 · Cited by 252
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
Danese, S., Fiorino, G., Raine, T., Ferrante, M., Kemp, K., Kierkuś, J., Lakatos, P. L., Mantzaris, G. J., van der Woude, C. J., Panés, J., et al. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjw198 · Cited by 251
Self-citation
Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis
Ferrante, M., D’Hoore, A. J. L., Vermeire, S., Declerck, S., Noman, M., Assche, G. V., Hoffman, I. E. A., Rutgeerts, P., & PENNINCKX, F. M. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20863 · Cited by 248
Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study
Sandborn, W. J., Travis, S. P. L., Moro, L., Jones, R., Gautille, T., Bagin, R. G., Huang, M., Yeung, P., & Ballard, E. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.08.003 · Cited by 245
Probiotics in the Management of Inflammatory Bowel Disease: A Systematic Review of Intervention Studies in Adult Patients
Jonkers, D., Penders, J., Masclee, A., & Pierik, M. (2012) · Drugs · doi:10.2165/11632710-000000000-00000 · Cited by 240
Outcome of cytomegalovirus infections in patients with inflammatory bowel disease
Papadakis, K., Tung, J. K., Binder, S. W., et al. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03949.x · Cited by 238
Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome
Kishore, J., Ghoshal, U., Ghoshal, U. C., Krishnani, N., Kumar, S., Singh, M., & Ayyagari, A. (2004) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45629-0 · Cited by 237
A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management
Gan, S. I., & Beck, P. L. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07696.x · Cited by 232
Perioperative Treatment with Infliximab in Patients with Crohn’s Disease and Ulcerative Colitis is Not Associated with an Increased Rate of Postoperative Complications
Kunitake, H., Hodin, R. A., Shellito, P. C., Sands, B. E., Korzenik, J. R., & Bordeianou, L. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-008-0630-8 · Cited by 230
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists
Feagan, B. G., Rubin, D. T., Danese, S., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.08.044 · Cited by 229
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis
Lawson, M., Thomas, A. G., & Akobeng, A. K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005112.pub2 · Cited by 229
6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease
Maté-Jiménez, J., Hermida, C., Perona, J. C., & Moreno‐Otero, R. (2000) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200012110-00010 · Cited by 228
Psychosocial determinants of relapse in ulcerative colitis: A longitudinal study
Bitton, A., Sewitch, M. J., Peppercorn, M. A., de B Edwardes, M. D., Shah, S., Ransil, B., & Locke, S. E. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07717.x · Cited by 226
An Assessment of Prednisone, Salazopyrin, and Topical Hydrocortisone Hemisuccinate Used as Out-patient Treatment for Ulcerative Colitis
Lennard‐Jones, J. E., Longmore, A. J., Newell, A. C., Wilson, C. W. E., & Jones, F. A. (1960) · Gut · doi:10.1136/gut.1.3.217 · Cited by 226
The long-term outcome of ulcerative colitis treated with 6-mercaptopurine.
George, J. M., Present, D. H., Pou, R., Bodian, C., & Rubin, P. (1996) · PubMed · Cited by 225
Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease
Torres, J., Boyapati, R. K., Kennedy, N. A., Louis, E. J., Colombel, J., & Satsangi, J. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.055 · Cited by 225
Long-term outcome after infliximab for refractory ulcerative colitis
Ferrante, M., Vermeire, S., Fidder, H. H., Schnitzler, F., Noman, M., Assche, G. V., Hertogh, G. D., Hoffman, I. E. A., D’Hoore, A., Steen, K. V., et al. (2008) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2008.03.004 · Cited by 222
Long-term Efficacy of Vedolizumab for Ulcerative Colitis
Loftus, E. V., Colombel, J., Feagan, B. G., Vermeire, S., Sandborn, W. J., Sands, B. E., Danese, S., D’Haens, G., Kaser, A., Panaccione, R., et al. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjw177 · Cited by 222
Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis
Ogata, H., Kato, J., Hirai, F., Hida, N., Matsui, T., Matsumoto, T., Koyanagi, K., & Hibi∥, T. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21853 · Cited by 212
Review article: defining remission in ulcerative colitis
Travis, S. P. L., Higgins, P., Orchard, T. R., van der Woude, C. J., Panaccione, R., Bitton, A., O'Morain, C. A., Panés, J., Sturm, A., Reinisch, W., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04701.x · Cited by 211
Cytomegalovirus infection in ulcerative colitis: A prospective, comparative study on prevalence and diagnostic strategy
Domènech, E., Vega, R., Ojanguren, I., Hernández, Á., García-Planella, E., Bernal, I., Rosinach, M., Boix, J., Cabré, E., & Gassull, M. A. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20498 · Cited by 210
Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies
Reinisch, W., Sandborn, W. J., Rutgeerts, P. J., Feagan, B. G., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., de Villiers, W. J. S., BLANK, M. A., Lang, Y., et al. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21697 · Cited by 208
Ciclosporin use in acute ulcerative colitis
Campbell, S. S., Travis, S. P. L., & Jewell, D. P. (2005) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200501000-00016 · Cited by 206
Assessment of severity in colitis: a preliminary study.
Lennard‐Jones, J. E., Ritchie, J. K., Hilder, W., & Spicer, C. C. (1975) · Gut · doi:10.1136/gut.16.8.579 · Cited by 205
Treatment of distal ulcerative colitis with short-chain fatty acid enemas a placebo-controlled trial
Scheppach, W. M., & German-Austrian Scfa Study Group (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02071409 · Cited by 204
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
Kruis, W., Kiudelis, G., Rácz, I. A., Gorelov, I. A., Pokrotnieks, J., Horyński, M., Bátovský, M., Kykal, J., Boehm, S. A., Greinwald, R., et al. (2008) · Gut · doi:10.1136/gut.2008.154302 · Cited by 204
The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Gisbert, J. P., Marín, A. C., & Chaparro, M. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.54 · Cited by 202
Biological Agents for Moderately to Severely Active Ulcerative Colitis
Danese, S., Fiorino, G., Peyrin‐Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L., & Bonovas, S. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2403 · Cited by 201
Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
Brandse, J. F., Mathôt, R. A. A., van der Kleij, D., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.10.029 · Cited by 201
Probiotics for induction of remission in ulcerative colitis
Mallon, P. T., McKay, D., Kirk, S. J., & Gardiner, K. R. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005573.pub2 · Cited by 197
Cyclosporine A for induction of remission in severe ulcerative colitis.
Shibolet, O., Regushevskaya, E., Brezis, M., & Soares-Weiser, K. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004277.pub2 · Cited by 195
Comparison of Corticosteroid and Sulphasalazine Therapy in Ulcerative Colitis
Truelove, S. C., Watkinson, G., & Draper, G. J. (1962) · BMJ · doi:10.1136/bmj.2.5321.1708 · Cited by 194
Probiotics for maintenance of remission in ulcerative colitis
Iheozor‐Ejiofor, Z., Kaur, L., Gordon, M. A., Baines, P. A., Sinopoulou, V., & Akobeng, A. K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007443.pub3 · Cited by 193
Predictors of early response to infliximab in patients with ulcerative colitis
Ferrante, M., Vermeire, S., Katsanos, K. H., Noman, M., Assche, G. V., Schnitzler, F., Arijs, I., Hertogh, G. D., Hoffman, I. E. A., Geboes, K. J., et al. (2006) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20054 · Cited by 192
Self-citation
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis
Green, J. R. B., Lobo, A., Holdsworth, C. D., Leicester, R. J., Gibson, J. A., Kerr, G. D., Hodgson, H. J. F., Parkins, K. J., & Taylor, M. D. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70627-4 · Cited by 191
Beclomethasone dipropionate (3mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3mg/2g) as retention enemas in active ulcerative proctitis
Mulder, C. J. J., Fockens, P., Meijer, J. W. R., van der Heide, H., Wiltink, H. H., & Tytgat, G. N. J. (1996) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199606000-00010 · Cited by 191
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study
Baumgart, D. C., Bokemeyer, B., Drabik, A., Stallmach, A., & Schreiber, S. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13594 · Cited by 187
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
Gecse, K. B., Lovasz, B. D., Farkas, K., et al. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv220 · Cited by 183
Why do patients with ulcerative colitis relapse?
Riley, S. A., Mani, V., Goodman, M. J., & Lucas, S. B. (1990) · Gut · doi:10.1136/gut.31.2.179 · Cited by 182
Tacrolimus Is Safe and Effective in Patients with Severe Steroid-Refractory or Steroid-Dependent Inflammatory Bowel Disease-A Long-Term Follow-Up
Baumgart, D. C., Pintoffl, J. P., Sturm, A., Wiedenmann, B. J., & Dignass, A. U. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00524.x · Cited by 182
Self-citation
Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis
Marshall, J. K., Thabane, M. E., Steinhart, A. H., Newman, J. R., Anand, A., & Irvine, E. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004115.pub2 · Cited by 180
Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study
Gustavsson, A., Järnerot, G., Hertervig, E., Friis–Liby, I., Blomquist, L., Karlén, P., Grännö, C., VILIEN, M., Ström, M., Verbaan, H., et al. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04435.x · Cited by 178
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
Kamm, M. A., Lichtenstein, G. R., Sandborn, W. J., Schreiber, S., Lees, K., Barrett, K., & Joseph, R. J. (2008) · Gut · doi:10.1136/gut.2007.138248 · Cited by 177
The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis.
Adler, D. J., & Korelitz, B. I. (1990) · PubMed · Cited by 173
Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis
Riley, S. A., Mani, V., Goodman, M. J., Herd, M. E., Dutt, S., & Turnberg, L. A. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90677-4 · Cited by 173
Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis.
Mantzaris, G. J., Hatzis, A., Kontogiannis, P., & Triadaphyllou, G. (1994) · PubMed · Cited by 171
Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
D'Albasio, G., Pacini, F., Camarri, E., Messori, A., Trallori, G., Bonanomi, A. G., Bardazzi, G., Milla, M., Ferrero, S., Biagini, M., et al. (1997) · PubMed · Cited by 170
Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements
Bitton, A., Buie, D. W., Enns, R. A., Feagan, B. G., Jones, J., Marshall, J. K., Whittaker, S., Griffiths, A. M., & Panaccione, R. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.386 · Cited by 170
Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up
Kohn, A., Daperno, M., Armuzzi, A., Cappello, M., Biancone, L., Orlando, A., Viscido, A., Annese, V., Riegler, G., Meucci, G., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03415.x · Cited by 169
Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies
Roberts, S., Williams, J. G., Yeates, D., & Goldacre, M. J. (2007) · BMJ · doi:10.1136/bmj.39345.714039.55 · Cited by 169
Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
Colombel, J., Sandborn, W. J., Ghosh, S. K., Wolf, D. C., Panaccione, R., Feagan, B. G., Reinisch, W., Robinson, A. M., Lazar, A., Kron, M., et al. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.242 · Cited by 166
Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study
Zenlea, T., Yee, E. U., Rosenberg, L., Boyle, M., Nanda, K. S., Wolf, J. L., Falchuk, K. R., Cheifetz, A. S., Goldsmith, J. D., & Moss, A. C. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.50 · Cited by 165
Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis
Sandborn, W. J., Targan, S. R., Byers, V. S., Rutty, D., Mu, H., Zhang, X., & Tang, T. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.340 · Cited by 161
Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis
Ford, A. C., Khan, K. J., Achkar, J., & Moayyedi, P. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.410 · Cited by 158
Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis.
Fernández‐Bañares, F., Bertrán, X., Esteve, M., Cabré, E., Menacho, M., Humbert, P., Planas, R., & Gassull, M. A. (1996) · PubMed · Cited by 154
Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis
Dignass, A. U., Bokemeyer, B., Adamek, H. E., Mross, M. R., Vinter‐Jensen, L., Börner, N., Silvennoinen, J., Tan, G., Pool, M. O., Stijnen, T., et al. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.04.004 · Cited by 154
Self-citation
Oral budesonide for induction of remission in ulcerative colitis
Sherlock, M. E., MacDonald, J. K., Griffiths, A. M., Steinhart, A. H., & Seow, C. H. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007698.pub3 · Cited by 151
Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis
Gionchetti, P., Rizzello, F., Venturi, A., Ferretti, M., Brignola, C., Miglioli, M., & Campieri, M. (1998) · Diseases of the Colon & Rectum · doi:10.1007/bf02236902 · Cited by 147
Clostridium difficile Infection in the Inflammatory Bowel Disease Patient
Berg, A. M., Kelly, C. P., & Farraye, F. A. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22964 · Cited by 146
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis
Carbonnel, F., Colombel, J., Filippi, J., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.10.050 · Cited by 144
Self-citation
Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis
Sandborn, W. J., Korzenik, J. R., Lashner, B. A., Leighton, J. A., Mahadevan, U., Marion, J. F., Safdi, M. A., Sninsky, C. A., Patel, R. M., Friedenberg, K., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.054 · Cited by 144
Toxic megacolon
Autenrieth, D., & Baumgart, D. C. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21847 · Cited by 143
A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis
Lees, C. W., Heys, D., Ho, G., Noble, C. L., Shand, A. G., Mowat, C., Boulton-Jones, R., WILLIAMS, A., Church, N. G., Satsangi, J., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03383.x · Cited by 140
Association Between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Outcomes in Acute Severe Ulcerative Colitis
Corte, C., Fernandopulle, N., Catuneanu, A. M., Burger, D. C., Cesarini, M., White, L., Keshav, S., & Travis, S. P. L. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv047 · Cited by 140
Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis
Carbonnel, Gargouri, Lémann, M., Beaugerie, Cattan, Cosnes, & Gendre (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00705.x · Cited by 139
Combination Immunomodulator and Antibiotic Treatment in Patients With Inflammatory Bowel Disease and Clostridium difficile Infection
Ben‐Horin, S., Margalit, M., Bossuyt, P. J., Maul, J., Shapira, Y., Bojic, D., Chermesh, I., Al‐Rifai, A., Schoepfer, A. M., Bosani, M., et al. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.031 · Cited by 139
Self-citation
Meta‐analysis: pre‐operative infliximab treatment and short‐term post‐operative complications in patients with ulcerative colitis
Yang, Z., Wu, Q., Wu, K., & Fan, D. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04204.x · Cited by 136
A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis
Sandborn, W. J., Tremaine, W. J., Schroeder, K. W., Batts, K. P., Lawson, G. M., Steiner, B. L., Harrison, J. M., & ZINSMEISTER, A. R. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90394-8 · Cited by 135
Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis
Pentasa UC Maintenance Study Group, Miner, P. B., Hanauer, S. B., ROBINSON, M. G., Schwartz, J., & Arora, S. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02065413 · Cited by 135
Remission induction and maintenance effect of probiotics on ulcerative colitis: A meta-analysis
Sang, L.-X. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i15.1908 · Cited by 133
Intravenous cyclosporine in attacks of ulcerative colitis
Carbonnel, F., Boruchowicz, A., Duclos, B., Soulé, J. C., Lerebours, É., Lémann, M., Bélaïche, J., Colombel, J., Cosnes, J., & Gendre, J. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02100145 · Cited by 131
Self-citation
High-Dose Methylprednisolone in the Treatment of Active Ulcerative Colitis
Rosenberg, W., Ireland, A., & Jewell, D. P. (1990) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199002000-00011 · Cited by 130
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?
Kefalakes, H., Stylianides, T. J., Amanakis, G., & Kolios, G. C. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0719-3 · Cited by 130
Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis
Navaneethan, U., Mukewar, S. S., Venkatesh, P. G. K., López, R., & Shen, B. (2011) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2011.09.005 · Cited by 129
Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets
Wright, R., & Truelove, S. (1966) · Digestive Diseases and Sciences · doi:10.1007/bf02233941 · Cited by 128
Probiotic Escherichia coli Nissle 1917 (EcN) for Successful Remission Maintenance of Ulcerative Colitis in Children and Adolescents: an Open-Label Pilot Study
Henker, J., Muller, S., Laass, M., Schreiner, A., & Schulze, J. (2008) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027463 · Cited by 128
Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease
Reinink, A. R., Lee, T. C., & Higgins, P. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000816 · Cited by 126
Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal
Cassinotti, A., Actis, G. C., Duca, P., Massari, A., Colombo, E. M., Gai, E., Annese, V., D'Albasio, G., Manes, G., Travis, S. P. L., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.410 · Cited by 125
Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications
Hyde, G. M., Jewell, D. P., Kettlewell, M. G. W., & Mortensen, N. J. M. C. (2001) · Diseases of the Colon & Rectum · doi:10.1007/bf02234594 · Cited by 125
Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit
Lynch, R. W., Lowe, D., Protheroe, A., Driscoll, R., Rhodes, J. M., & Arnott, I. D. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12473 · Cited by 124
Infliximab, Azathioprine, or Infliximab + Azathioprine for Treatment of Moderate to Severe Ulcerative Colitis: The UC Success Trial
Panccione, R., Ghosh, S. K., Middleton, S. J., Márquez, J. R., Халиф, И. Л., Flint, L., van Hoogstraten, H., Zheng, H., Danese, S., & Rutgeerts, P. J. (2011) · Gastroenterology · doi:10.1016/s0016-5085(11)60548-9 · Cited by 120
Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease
Jen, M., Saxena, S. K., Bottle, A., Aylin, P. P., & Pollok, R. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04661.x · Cited by 119
Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials
Regueiro, M. D., Loftus, E. V., Steinhart, H., & Cohen, R. D. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000231495.92013.5e · Cited by 117
First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses
Karner, M., Kocjan, A., Stein, J. M., Schreiber, S., von Boyen, G. B. T., Uebel, P., Schmidt, C., Kupčinskas, L., Dina, I., Zuelch, F., et al. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.104 · Cited by 117
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006
Jakobovits, S. L., Jewell, D. P., & Travis, S. P. L. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03300.x · Cited by 116
Long‐term effect of tacrolimus therapy in patients with refractory ulcerative colitis
YAMAMOTO, S., Nakase, H., MIKAMI, S., Inoue, S., Yoshino, T., Takeda, Y., Kasahara, K., UENO, S., Uza, N., Kitamura, H., et al. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03764.x · Cited by 115
The efficacy of methotrexate for maintaining remission in inflammatory bowel disease
Fraser, A. G., Morton, D., McGovern, D. P. B., Travis, S. P. L., & Jewell, D. P. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01227.x · Cited by 114
Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers
Travis, S. P. L., Satsangi, J., & Lémann, M. (2010) · Gut · doi:10.1136/gut.2010.216895 · Cited by 111
Azathioprine in Steroid-Resistant and Steroid-Dependent Ulcerative Colitis
Ardizzone, S., Molteni, F., Imbesi, V., Bollani, S., & Porro, G. B. (1997) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199707000-00007 · Cited by 111
52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants
Reinisch, W., Sandborn, W. J., Panaccione, R., Huang, B., Pollack, P. F., Lazar, A., & Thakkar, R. B. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f2b7 · Cited by 110
A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis
Kane, S. V., Huo, D., & Magnanti, K. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)70032-9 · Cited by 110
Budesonide Foam Induces Remission in Patients With Mild to Moderate Ulcerative Proctitis and Ulcerative Proctosigmoiditis
Sandborn, W. J., Bosworth, B. P., Zakko, S. F., Gordon, G. L., Clemmons, D. R., Golden, P. L., Rolleri, R. L., Yu, J., Barrett, A. C., Bortey, E. B., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.037 · Cited by 109
The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis
Sood, A., Kaushal, V., Midha, V., Bhatia, K. L., Sood, N., & Malhotra, V. (2002) · Journal of Gastroenterology · doi:10.1007/s005350200034 · Cited by 109
Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis
Feagan, B. G., Sandborn, W. J., Lazar, A., Thakkar, R. B., Huang, B., Reilly, N., Chen, N., Yang, M., Skup, M., Mulani, P. M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.09.032 · Cited by 108
Limited exposure of the healthy distal colon to orally‐dosed formulation is further exaggerated in active left‐sided ulcerative colitis
Hebden, BLACKSHAW, Perkins, Wilson, & Spiller, R. E. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00697.x · Cited by 107
European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease
van Rheenen, P. V., Aloi, M., Biron, I., Carlsen, K., Cooney, R., Cucchiara, S., Cullen, G., Escher, J., Kierkuś, J., Lindsay, J., et al. (2017) · Journal of Crohn's & Colitis · doi:10.1093/ecco-jcc/jjx010 · Cited by 107
Self-citation
Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial
Bossa, F., Fiorella, S., Caruso, N., Accadia, L., Napolitano, G., Valvano, M. R., Andriulli, A., & Annese, V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.01007.x · Cited by 104
Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort
Gies, N., Kroeker, K. I., Wong, K., & Fedorak, R. N. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04380.x · Cited by 103
Small bowel gas in severe ulcerative colitis.
Chew, C. N., Nolan, D. J., & Jewell, D. P. (1991) · Gut · doi:10.1136/gut.32.12.1535 · Cited by 103
Oral beclometasone dipropionate in the treatment of extensive and left‐sided active ulcerative colitis: a multicentre randomised study
Campieri, M., Adamo, S., Valpiani, D., D’Arienzo, A., D'Albasio, G., Pitzalis, M. V., Cesari, P., Casetti, T., Castiglione, G. N., Rizzello, F., et al. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01609.x · Cited by 102
Long-Term Use of Mesalamine (Rowasa) Suppositories in Remission Maintenance of Ulcerative Proctitis
Hanauer, S. B., Good, L. I., Goodman, M. W., Pizinger, R. J., Strum, W. B., Lyss, C., Haber, G. B., Williams, N. C., & ROBINSON, M. G. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02185.x · Cited by 102
Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study
Marteau, P. R., Crand, J., Foucault, M., & Rambaud, J. C. (1998) · Gut · doi:10.1136/gut.42.2.195 · Cited by 102
Narcotic use for inflammatory bowel disease and risk factors during hospitalization
Long, M. D., Barnes, E. L., Herfarth, H. H., & Drossman, D. A. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21806 · Cited by 100
Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis
Cacheux, W., Seksik, P., Lémann, M., Marteau, P. R., Nion–Larmurier, I., Afchain, P., Daniel, F. E., Beaugerie, L., & Cosnes, J. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01653.x · Cited by 100
Helminth therapy (worms) for induction of remission in inflammatory bowel disease
Garg, S. K., Croft, A. M., & Bager, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009400.pub2 · Cited by 99
Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study
Actis, G. C., Fadda, M., David, E., & Sapino, A. (2007) · BMC Gastroenterology · doi:10.1186/1471-230x-7-13 · Cited by 99
Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine
Wahed, M., Louis-Auguste, J., Baxter, L. M., Limdi, J. K., McCartney, S. A., Lindsay, J. O., & Bloom, S. L. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04073.x · Cited by 97
Clinical Predictors of Colectomy in Patients with Ulcerative Colitis: Systematic Review and Meta-analysis of Cohort Studies
Dias, C. C., Rodrigues, P. P., Costa‐Pereira, A., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jju016 · Cited by 97
Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis
Komaki, Y., Komaki, F., Ido, A., et al. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv221 · Cited by 93

Research works printed but not linked: 11

1997, A double-blind comparison of oral vs rectal mesalamine vs combination therapy in the treatment of distal ulcerative colitis, Am J Gastroenterol, 92, 1867
2010, Oral budesonide for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, CD007698
Epidemiology and Natural History Task Force of the International Organization of the Study of Inflammatory Bowel Disease, 2013, A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease, Inflamm Bowel Dis, 19, 2001
2003, Randomized, double-blind comparison of 4 mg/kg vs 2 mg/kg intravenous cyclosporine in severe ulcerative colitis, Gastroenterology, 125, 1025
1993, Enteral vs parenteral nutrition as adjunct therapy in acute ulcerative colitis, Am J Gastroenterol, 88, 227
1994, Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity, Dig Dis Sci, 39, 1550
2005, Pattern and outcome of severe ulcerative colitis: 15 year data, Gut, 54, A155
2012, Mucosal healing with infliximab: results from the active ulcerative colitis trials, Gastroenterol Hepatol, 8, 117
1994, The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis, Gastroenterology, 106, A736
2003, Azathioprine vs sulfasalazine in maintenance of remission in severe ulcerative colitis, Indian J Gastroenterol, 22, 79
GEMINI 1 Study Group, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 369, 699, 10.1056/NEJMoa1215734 · DOI

Sorted by citations

Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis
Barberio, B., Zamani, M., Black, C. J., Savarino, E. V., & Ford, A. C. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00014-5 · Cited by 758
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
The Unregulated Probiotic Market
de Simone, C. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.01.018 · Cited by 317
Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice
Torres, J., Hu, J., Seki, A., Eisele, C., Nair, N., Huang, R., Tarassishin, L., Jharap, B., Cote-Daigneault, J., Mao, Q., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317855 · Cited by 218
Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial
Kedia, S., Virmani, S., K Vuyyuru, S., Kumar, P., Kante, B., Sahu, P., Kaushal, K., Farooqui, M., Singh, M., Verma, M., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327811 · Cited by 201

See all 1,180

Authors: Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., de Sousa, H. T., Dignass, A., Carbonnel, F., & for the European Crohn’s and Colitis Organisation [ECCO
Affiliations: Chelsea and Westminster Hospital (GB)
Sheba Medical Center (IL)
University Hospital Münster (DE)
Department of Gastroenterology, Venizeleio General Hospital d , Heraklion, Crete , Greece
University of Ioannina (GR)
Tel Aviv University (IL)
Klinikum Lüneburg (DE)
University of Szeged (HU)
University of Cambridge (GB)
Hull University Teaching Hospitals NHS Trust (GB)
Gastroenterology Department, Algarve Hospital Center; Biomedical Sciences & Medicine Department, University of Algarve k , Faro , Portugal
Agaplesion Markus Hospital (DE)
Université Paris-Sud (FR)
Corresponding author: Harbord, Marcus
ORCID: Bettenworth, Dominik
Kopylov, Uri
Kucharzik, Torsten
Molnár, Tamás
Raine, Tim
Sebastian, Shaji
Dignass, Axel
Carbonnel, Franck
Venue: Journal of Crohn's and Colitis
Publisher: Oxford University Press (OUP)
Published: 2017-01-28
Volume: 11
Issue: 7
Pages: 769-784
ISSN: 1873-9946 (ISSN-L)
1876-4479
DOI: 10.1093/ecco-jcc/jjx009
OpenAlex: W4210662453
Cited by: 1,180
References: 309
Citations by year: 2026: 49 · 2025: 101 · 2024: 103 · 2023: 130 · 2022: 166 · 2021: 179 · 2020: 174 · 2019: 149 · 2018: 110 · 2017: 17
FWCI: 81.69
Type: journal article
Language: en
Update notices: expression_of_concern (2022-01-24)
Open access: bronze
doi.org
Locations: Journal of Crohn s and Colitis (publishedVersion)
SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
Topics: Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
Keywords: ulcerative colitis, proctitis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks